Immutep (IMMP) Assets (2011 - 2026)
Immutep's (IMMP) quarterly Assets came in at $59.1 million in Q2 2026, down 41.25% on a YoY basis from $100.5 million in Q2 2025, and down 38.89% quarter-over-quarter from $96.6 million in Q4 2025.
Analysis
Immutep (IMMP) Assets (2011 - 2026) Analysis & Trends
Immutep (IMMP) has reported Assets for 16 consecutive years, with $59.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Assets fell 41.25% year-over-year to $59.1 million; the trailing twelve-month figure through Jun 2026 stood at $59.1 million (down 41.25% YoY), and the FY2026 full-year result was $59.1 million, down 41.25% from the prior year.
- Assets retreated to $59.1 million in Q2 2026 per IMMP's latest filing, from $96.6 million in the prior quarter.
- Across five years, Assets topped out at $132.8 million in Q2 2024 and bottomed at $56.5 million in Q4 2022.
- Historically, Assets has averaged $90.8 million across 5 years, with a median of $96.6 million in 2025.
- The sharpest annual moves came in 2024 and 2026: Assets soared 47.96% in 2024, then plunged 41.25% in 2026.
- Over 5 years, Assets stood at $56.5 million in 2022, then surged by 42.6% to $80.6 million in 2023, then surged by 47.96% to $119.2 million in 2024, then dropped by 18.94% to $96.6 million in 2025, then sank by 38.89% to $59.1 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $59.1 million, $96.6 million, and $100.5 million for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 95.64 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 49.36 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 27.42 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 41.73 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 10.03 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 10.96 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 32.09 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 5.31 Bn |
| 10 | Immutep | 51.68 Mn | 51.68 Mn | - | 59.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 59.07 Mn |
| Dec 31, 2025 | 96.65 Mn |
| Jun 30, 2025 | 100.54 Mn |
| Dec 31, 2024 | 119.23 Mn |
| Jun 30, 2024 | 132.85 Mn |
| Dec 31, 2023 | 80.59 Mn |
| Jun 30, 2023 | 98.55 Mn |
| Dec 31, 2022 | 56.51 Mn |
| Jun 30, 2022 | 73.18 Mn |
| Dec 31, 2021 | 87.57 Mn |
| Jun 30, 2021 | 63.17 Mn |
| Dec 31, 2020 | 55.90 Mn |
| Jun 30, 2020 | 30.54 Mn |
| Dec 31, 2019 | 29.35 Mn |
| Jun 30, 2019 | 28.40 Mn |
| Dec 31, 2018 | 34.61 Mn |
| Jun 30, 2018 | 35.58 Mn |
| Dec 31, 2017 | 28.49 Mn |
| Jun 30, 2017 | 26.27 Mn |
| Mar 31, 2017 | 26.78 Mn |